Merck Outlines Strategic Shift Toward Clinical Trial Simplification and AI Integration
At the 2026 SCOPE Summit, Dr. Eliav Barr, Head of Global Clinical Development and Chief Medical Officer at Merck...
Arcutis’ Zoryve Cream: A Promising Trial for Infant Eczema
Fifty-eight percent of infants treated with roflumilast cream 0.05% achieved EASI-75 at Week 4 in an open-label Phase 2...
Successful Milestone for Actinogen’s Alzheimer’s Trial
An independent Data Monitoring Committee reviewed unblinded interim data from approximately 37% of Actinogen’s pivotal XanaMIA Alzheimer’s disease trial...
Successful 52-Week Phase 3 Acne Trial Data for ASC40
Denifanstat’s long-term safety profile in acne was clean in Ascletis’ open-label Phase 3 extension: among 240 patients treated once...
Landmark Study Reveals Molecular Roadmap of Brain Aging
141 living cortical samples from neurosurgical patients, paired with MRI and multi-omics profiling across more than 100,000 cells, revealed...
Successful Venglustat Phase 3 Trial Offers Hope for Gaucher
Sanofi’s brain-penetrant GCS inhibitor venglustat met the primary endpoint and three of four key secondary endpoints in the Phase...
Venglustat Breakthrough in Phase 3 Gaucher Disease Study
In the Phase 3 LEAP2MONO study (n=43), venglustat achieved statistically significant improvement in neurological function at week 52 versus...
Crinetics Initiates Phase 2/3 Pediatric Trial for CAH
Crinetics’ atumelnant has previously shown statistically significant 12‑week reductions in androstenedione and 17‑hydroxyprogesterone in Phase 2, and the company...
Pioneering Trial: 4D Path Advances Bladder Cancer Biomarkers
4D Path’s QPOR platform has been selected as an exploratory biomarker in the Phase II DAD-IO study (NCT04724018) in...
Aprea WEE1 Inhibitor Trial Shows Early Proof-of-Concept
A single patient with PPP2R1A-mutated uterine serous carcinoma achieved an unconfirmed partial response with a 50% reduction in target...